GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

pivekimab sunirine   Click here for help

GtoPdb Ligand ID: 14543

Synonyms: Decnupaz® | IMGN 632 | IMGN-632 | IMGN632 | pivekimab sunirine-pvzy | PVEK [2]
Approved drug
pivekimab sunirine is an approved drug
Compound class: Antibody
Comment: Pivekimab sunirine (IMGN632) is an interleukin 3 receptor subunit alpha (IL3RA) antibody-drug conjugate [2,4]. The payload is a DNA mono-alkylating compound (a monoamine indolinobenzodiazepine pseudodimer) [1]. The antibody is intended to deliver the toxic conjugate to neoplastic blood cells that overexpress IL3RA [5-6].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Pivekimab sunirine (IMGN-632) was progressed as a clinical candidate for the treatment of IL3RA (CD123)-overexpressing haematological malignancies. It was granted FDA orphan drug designations for the treatment of acute myeloid leukemia (AML; 2018) and blastic plasmacytoid dendritic cell neoplasm (BPDCN; 2020). The FDA approved pivekimab sunirine in May 2-26, to treat BPDCN.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03386513 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Phase 1/Phase 2 Interventional AbbVie The CADENZA study 3
NCT06034470 Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms Phase 1 Interventional Fred Hutchinson Cancer Center
NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia Phase 1/Phase 2 Interventional AbbVie